Aurelius Health Group review

A physician-titrated microdose tirzepatide protocol is the only thing sold here, which makes this the purest version of what you came for: so there is no full-dose ladder waiting to absorb you and no membership stacked underneath the medication. A board-certified physician reviews the intake inside a day and issues a written plan and titration schedule, and one care-inclusive figure covers the protocol, the consultations, shipping and monitoring. The reservation is not commercial, it is evidential. Its homepage argues the case with a comparison table of expected nausea rates, lean-mass retention and result ranges at a microdose — figures its own footnotes concede are extrapolated from dose-ranging and observational data rather than measured on the protocol being sold. Printing the footnote is to its credit; leading with the table is the overreach this site exists to name.

Vs median

$30/mo above the $169 median across the 261 of 407 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Prices the low dose on its own

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Varies by dose, plan or tier

Aurelius Health Group does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

A single-product practice: physician-titrated microdose tirzepatide, with a board-certified MD or DO reviewing the intake inside 24 hours and issuing a written plan and titration schedule. There is no full-dose ladder to be upsold onto, which removes the usual pressure a microdoser feels on a general platform, and the price is one care-inclusive figure rather than a medication rate with consults and shipping billed underneath. The reservation is not the price. It is that the site argues its case with a comparison table of expected results at a 1 mg microdose, sourced to observational and dose-ranging data rather than to any trial of the protocol it sells.

The homepage prints expected nausea rates, lean-mass retention and result ranges for a 1 mg microdose — figures extrapolated from full-dose and observational data, not measured on the protocol being sold, which is exactly the overreach this site was built to flag

• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven
• Tirzepatide only, injectable only — there is no semaglutide option and no needle-free route
• The $89 is a single introductory month; the standing rate is more than double it
• Neither the compounding pharmacy nor any individual physician is named on the public site

Aurelius Health Group is one of 407 low-dose GLP-1 programs compared on this site, and 261 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• Microdosing tirzepatide
• Low dose vs full dose
• Titration planner
• Microdose & reconstitution calculator